Log In
BCIQ
Print this Print this
 

TMA

  Manage Alerts
Collapse Summary General Information
Company Rare Partners s.r.l.
Description4,6,4'-trimethylangelicin (TMA)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationCystic fibrosis (CF)
Indication DetailsTreat cystic fibrosis (CF)
Regulatory Designation EU - Orphan Drug (Treat cystic fibrosis (CF))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today